

# Results of the 1<sup>st</sup> Quarter 2013/14

Investor Call  
Mannheim, 25<sup>th</sup> June 2013

PHOENIX group

Reimund Pohl  
CEO

Dr. Michael Majerus  
CFO



© 2013 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the “Company” and, together with its subsidiaries and affiliates, “PHOENIX”) solely in connection with the release of the results of the 1<sup>st</sup> quarter 2013/14 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the “Parties”) as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words “targets”, “believes”, “expects”, “aims”, “intends”, “may”, “anticipates”, “would”, “could” or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.

## Highlights 1<sup>st</sup> Quarter 2013/14 and Current Developments within PHOENIX group




Reimund Pohl  
CEO

## Group Financials 1<sup>st</sup> Quarter 2013/14



Dr. Michael Majerus  
CFO


## Questions & Answers



Despite the challenging market situation, PHOENIX was able to grow dynamically and maintain a stable business development

- Strong increase in total operating performance and net turnover, significantly above the market trend
- Intensive competition leads to a decrease in total income
- Profit before tax stable compared to previous year
- Once again, PHOENIX was able to improve its ratio of net debt to adjusted EBITDA

### Negative trend in European pharma market continues\*




### Market Growth in key markets:

- Germany: **+0.8%**
- France: **-3.4%**
- Italy: **-2.3%**
- UK: **-3.8%**
- Sweden: **-4.2%**
- Netherlands: **-9.3%**

\* Source: IMS Health Executive Market Report


# PHOENIX has differentiated itself from the negative market trend, but experiences pressure on margins




\* Non-IFRS measure. Includes net turnover and handled volume (goods distributed under fee-for-service agreements)

\*\* Total income restated for 2012/13 due to reclassification of transport costs

# Operating expenses remain stable due to active cost management and productivity gains



# PHOENIX has been able to maintain its profitability in the first quarter 2013/14



## Important milestones and strategic priorities

- Enhancement of profitability through **PHOENIX FORWARD**
- **Refinement of business processes** in wholesale and retail
- Increased focus on **services for pharmaceutical manufacturers**
- Further optimization of **capital structure** and **net working capital**
- **Organic growth**
- **Selected acquisitions**



## Group Financials 1<sup>st</sup> Quarter 2013/14



Dr. Michael Majerus  
CFO

## Questions & Answers

Despite the challenging market environment, the P&L shows a profit before taxes on the same level as in the year before

Profit & Loss	Q1 2012/13*		Q1 2013/14		Delta	
	in m€	%	in m€	%	in m€	%
<b>Net turnover</b>	<b>5,197.4</b>	<b>100%</b>	<b>5,340.1</b>	<b>100%</b>	<b>142.7</b>	<b>2.7%</b>
Cost of goods sold	-4,666.3	-89.8%	-4,830.9	-90.5%	-164.6	3.5%
<b>Gross profit</b>	<b>531.1</b>	<b>10.2%</b>	<b>509.2</b>	<b>9.5%</b>	<b>-21.9</b>	<b>-4.1%</b>
Other operating income	38.6	0.7%	40.1	0.8%	1.4	3.8%
Personnel expenses	-267.2	-5.1%	-265.6	-5.0%	1.6	-0.6%
Other operative expenses	-172.8	-3.3%	-178.1	-3.3%	-5.3	3.1%
Result from associates and other invest.	0.5	0.0%	0.5	0.0%	0.0	8.5%
<b>EBITDA</b>	<b>130.3</b>	<b>2.5%</b>	<b>106.1</b>	<b>2.0%</b>	<b>-24.1</b>	<b>-18.5%</b>
Depreciations	-24.7	-0.5%	-26.1	-0.5%	-1.4	5.7%
Financial result	-52.2	-1.0%	-26.8	-0.5%	25.4	-48.6%
<b>Profit before taxes</b>	<b>53.4</b>	<b>1.0%</b>	<b>53.2</b>	<b>1.0%</b>	<b>-0.2</b>	<b>-0.3%</b>
Income taxes total	-15.5	-0.3%	-17.9	-0.3%	-2.4	15.8%
<b>Profit for the period</b>	<b>37.9</b>	<b>0.7%</b>	<b>35.3</b>	<b>0.7%</b>	<b>-2.6</b>	<b>-6.9%</b>

## Developments

- **Net turnover** significantly improved, mainly due to the good development in the German market, but also good development in other European markets
- Due to the special situation in Germany vs. previous year **gross profit** decreased: In the 1<sup>st</sup> quarter 2012/13 PHOENIX aimed at profit stabilization, which resulted in a higher gross profit
- Whereas **other operating income** and **personnel expenses** developed well, other **operative expenses** increased especially due to transport costs and a higher level of bad debt provisions
- **Depreciations** slightly increased
- Also excluding the one-time effect of the dissolution of transaction costs (-18.4 m€) in the previous year, the **financial result** has improved by approx. +7 m€ thanks to the reduced net debt and better financing conditions
- The **profit before taxes** is on the same level as in the prior year
- The **tax rate** is at 33.7% compared to 29% in the previous year, mainly due to volatility of the Estimated Effective Tax Rate (EETR) approach of IAS 34. Within the current fiscal year a tax rate in the range of the previous year is expected

\* PY adjusted for reclassification of transport costs and due to the first-time adoption of IAS 19R

# PHOENIX group's optimized financial structure improves the interest result

Financial result (in m€)	Q1 2012/13**	Q1 2013/14	Delta
Interest income	6.3	6.2	-0.1
Interest expenses	-39.9	-33.8	6.1
<b>Interest result</b>	<b>-33.6</b>	<b>-27.6</b>	<b>6.0</b>
Dissolution of transaction costs due to premature refinancing	-18.4	0.0	18.4
Other net financial result*	-0.2	0.8	1.0
<b>Financial result</b>	<b>-52.2</b>	<b>-26.8</b>	<b>25.4</b>

## Developments

- Slight reduction of interest income
- Lower interest expenses are mainly driven by reduced debt and optimized interest rates
- Most influencing factor in previous year was the premature refinancing of PHOENIX group, resulting in the dissolution of corresponding transaction costs


\* Other net financial result comprises

- “other financial income and expenses“,
- “financial income and expenses from derivatives” as well as
- “exchange rate gains and losses” related to the financial result

\*\* Prior year restated due to the first-time adoption of IAS 19R

# PHOENIX continues its committed path of strengthening its balance sheet

(m€)



- ### Developments
- Equity ratio further improved by profit for the period
  - Financial liabilities increased due to seasonal increase of NWC
  - Inventories and trade receivables slightly increased due to higher turnover and seasonal pattern
  - Trade payables decreased
  - Despite absolute increase of NWC (-189.0 m€ vs. YE 2012/13), measured in average NWC days, NWC is lower than year-end and previous year's 1<sup>st</sup> quarter:
    - NWC days Q1 2011/12: 38.6
    - NWC days YE 2012/13: 37.5
    - NWC days Q1 2012/13: 37.0


- Equity
- Other
- Net Working Capital
- Financial Liabilities
- Cash & Equivalents

Balance ratio

# Net debt has significantly improved compared to previous year, again

(m€)

04/30/2013



## Developments


- Reclassification within financial liabilities due to new SFA (June 2012)
  - Tranche with 300 m€ for 4 years within long term liabilities
  - Revolving facility (max. 1.05 bn€) as needed within short term liabilities
- Net debt reduction of 266 m€ compared to Q1 2012/13:
  - Reduction of net financial liabilities by 220 m€
  - Decrease of ABS/factoring by 50 m€

# The renewal of the syndicated bank facilities improves the maturity profile

## Financial facilities and headroom

(m€)

04/30/2013




- Diversified financing structure
- Significant financial headroom and efficient utilisation of cash allowed reduction of credit lines

## Debt maturity profile

(m€)

04/30/2013




- Renewal of SFA extended the duration and better distributes the maturities
- ABS/factoring actively managed and extended to some parts

# PHOENIX successfully placed a new Bond in May 2013

<b>Targets</b>	<ul style="list-style-type: none"><li>▪ Securing the historical low level of interest</li><li>▪ Further diversification of the maturity profile of the credit facilities</li><li>▪ Strengthening the presence of PHOENIX group at the capital markets</li></ul>
<b>Key Facts</b>	<ul style="list-style-type: none"><li>▪ Volume: 300 m€</li><li>▪ Term: 7 years</li><li>▪ Interest: 3.125% p.a. with an initial yield of 3.25% p.a.</li><li>▪ Minimum invest: 100,000 €</li><li>▪ The issue was oversubscribed approximately 10 times. The order book contained an invest interest of around 3 bn€</li></ul>
<b>Rating</b>	<ul style="list-style-type: none"><li>▪ Both Standard &amp; Poor's and Fitch have assigned a rating of "BB" to the new bond</li><li>▪ This corresponds to the respective company rating and the rating for the bond that was issued in 2010</li></ul>

# The active management of net working capital shows significant improvements




<h3>Key Achievements</h3>	<ul style="list-style-type: none"> <li>■ Slight increase in stock due to higher turnover</li> <li>■ Trade receivables in absolute figures on a comparable level despite higher turnover, but on a daily base improved</li> <li>■ Payables absolutely increased; on a daily base improved vs. previous year</li> <li>■ Overall, significantly improved NWC</li> </ul>
---------------------------	--

• Balance sheet figures as externally reported  
 • Net working capital days: Average figures for the respective period; figures including ABS/factoring; may include rounding differences



# Free cash flow development



## Cash flow development

- The cash flow before changes in working capital (column I + II) is slightly lower due to the lower level of EBITDA and a higher level of paid taxes
- Negative development within working capital (measured against year-end 2012/13 and year-end 2011/12) is driven by the different turnover development: Whereas in previous year the turnover reduction led especially to lower trade receivables, this year the turnover growth resulted in higher trade receivables, starting from a lower overall level at year-end 2012/13
- Cash flow from investing activities is slightly decreased due to lower investments in fixed assets and higher cash inflows from the disposal of fixed assets
- Compared to previous year's 1<sup>st</sup> quarter lower level of free cash flow

\* Prior year restated due to the first-time adoption of IAS 19R


# Summary: Development of key credit indicators

	01/31/2013	04/30/2013	Delta
Equity (in m€)	2,103.8	2,149.8	2.2%
Equity ratio	28.7%	29.3%	+0.6pp
Net debt (in m€)	1,611.5	1,784.0	10.7%
Gearing (Net debt/equity)	76.6%	83.0%	+6.4pp
	Q1 2012/13	Q1 2013/14	Delta
EBITDA (in m€)	130.3	106.1	-18.5%
EBITDA-margin	2.5%	2.0%	-0.5pp
Adjusted EBITDA (in m€)	136.5	111.3	-18.4%
Adj.-EBITDA-margin	2.6%	2.1%	-0.5pp
<b>Net debt / adjusted EBITDA (LTM)</b>	<b>3.67</b>	<b>3.23</b>	<b>-12.0%</b>
Interest coverage ratio ** (EBIT / Interest Expenses*)	2.6	2.4	-10.5%
Profit before tax (in m€) **	53.4	53.2	-0.3%
PBT-margin **	1.0%	1.0%	0.0pp
Profit after tax (in m€) **	37.9	35.3	-6.9%
PAT-margin **	0.7%	0.7%	0.0pp

\* Interest expenses excluding fx-effects and other financial expenses


\*\* Prior year restated due to the first-time adoption of IAS 19R

# Developments of PHOENIX' bonds



Source: Bloomberg, 06/19/2013

# The outperformance of the 1<sup>st</sup> PHOENIX bond is shown by the spread to the iBoxx high-yield index



\*Yield to maturity minus swap rate  
Date 06/19/2013

## Key messages

- Continuously improve the capital structure by reducing the level of indebtedness
- Aim to further strengthen the equity ratio by retaining profits in the medium term
- Maintain ratio of Net Debt to Adj. EBITDA of around 3.0x
- Long-term safeguarding of liquidity via well-balanced and diversified funding sources

## Liquidity & Risk management

- Centralized group funding – Financing of subsidiaries through intra-group loans, except for local ABS/Factoring programs and for the total Italian subgroup
- Centralized cash pooling structure within PHOENIX group
- Well-diversified corporate financing structure
- Financial derivatives only used for hedging purposes, not for speculation

## Growth strategy

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions may also be pursued, but only within a predefined acquisition budget

Our shareholder fully backs our financial policy

## Financial outlook of PHOENIX group for the fiscal year 2013/14:

---

- On the whole, we do not expect the pharmaceutical markets in Europe to record any growth in the fiscal year 2013/14
- Despite this current period of market weakness, we expect revenue to increase slightly in 2013/14, especially due to Germany, where we anticipate a tangible increase in revenue in 2013/14 after reporting a decline in 2012/13
- With regard to adjusted EBITDA, we do not expect to reach the 2012/13 level in the fiscal year 2013/14 on account of the unfavorable market environment
- Significant positive effects from the PHOENIX FORWARD program will most likely arise as of fiscal year 2014/15

Reporting Event	Date
Results of the 1 <sup>st</sup> half-year 2013/14	Tuesday, 09/24/2013
Results of the 3 <sup>rd</sup> quarter 2013/14	Thursday, 12/19/2013



**PHOENIX** group